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The immune response in the nasal mucosa to influenza vaccination in 23 patients scheduled for
tonsillectomy was studied. A statistically significant increase in influenza virus–specific serum
and oral fluid antibodies was observed 7 days after vaccination. The numbers of influenza virus–
specific antibody-secreting cells (ASCs) in peripheral blood also increased significantly 1 week
after vaccination. The numbers of ASCs in tonsils and nasal mucosa were compared with data
from a recent study of nonvaccinated volunteers. The numbers of influenza virus– specific
ASCs in tonsils were significantly higher in the vaccinated group, but, surprisingly, there was
no significant difference between the groups in the numbers of ASCs in nasal mucosa. This
suggests that the influenza virus–specific antibodies detected in oral fluid are not produced lo-
cally in the nasal mucosa and may originate from a systemic source, indicating that the vacci-
nation may favor a systemic immune response.
Influenza virus is a common respiratory pathogen; it causes
high morbidity in the general population and high mortality in
at-risk groups. The annual costs associated with influenza, in-
cluding the cost of hospitalization, disease treatment, and loss
of productivity, are considerable [1].
For many years, vaccination has been the major method of in-
fluenza prophylaxis. Recently, several antiviral drugs have been
developed for therapeutic and prophylactic use. Despite vast in-
vestment in anti–influenza virus drugs, influenza vaccination re-
mains the major and most cost-effective method of prophylaxis.
Two factors that have been considered important to production
of an effective influenza vaccine are the antigenic match be-
tween strains included in the vaccine and those circulating in
the community and the vaccine’s ability to stimulate the produc-
tion of serum antibodies, as tested by the hemagglutination
inhibition (HAI) assay.
In previous studies, we investigated the humoral immune re-
sponse induced by parenteral influenza vaccination and natural
infection [2–5]. We found that parenteral influenza vaccination
induced a rapid and strong systemic immune response [2, 3],
whereas the local immune response was equally rapid but more
transient [3, 4]. More recently, we have examined in greater
detail the basal levels of influenza virus–specific antibody-secret-
ing cells (ASCs) in blood, tonsils, and nasal mucosa [5]. The
results from this study are interesting because, although none
of the study subjects had been recently vaccinated or naturally
infected with influenza virus, it was still possible to detect low
levels of influenza virus–specific ASCs in all compartments [5].
We also found that the frequency of influenza virus–specific
ASCs among the isolated lymphocytes was 10–100 times higher
in the nasal mucosa than in the blood and tonsils [5].
The aim of the present study was to examine the effect of par-
enteral influenza vaccination on the numbers of influenza virus–
specific ASCs locally in the tonsils and nasal mucosa.
Patients, Materials, and Methods
Patients and samples. Samples for immunologic testing were
obtained from 23 volunteers (11 male and 12 female; mean age,
26 years) who were scheduled for tonsillectomy at the Haukeland
University Hospital (Bergen, Norway) during August to December
2000. The subjects were chosen from among patients with recurrent
tonsillitis who were otherwise healthy. The patients had not experi-
enced any infection during the preceding 3 months, had no history
of allergy, and had not been immunized or infected with influenza
virus during the last few years. One week before the operation, pe-
ripheral blood was collected by intravenous punture, and oral fluid
was collected with an absorbent pad on a stick (Orasure; Epitope),
and the subjects were vaccinated with influenza vaccine (Fluarix;
SmithKline Beecham). The trivalent vaccine consisted of 15 mg of
hemagglutinin (HA) from each of the following virus strains: A/
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New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/
Yamanashi/166/98. Seven days later, bilateral tonsillectomy was
done. Blood and oral fluid were collected a second time from the
volunteers. In addition, the adenoid tonsils and a nasal mucosal
biopsy sample from the middle portion of the caudal medial part
of the inferior turbinate were collected from 8 of the patients.
A blood sample was collected before the vaccination, in conjunc-
tion with the clinical examination of the patients. These samples
were sent to the laboratory at Haukeland University Hospital and
analyzed for antibodies to influenza A virus, influenza B virus, para-
influenza viruses, and common allergens, in addition to analysis in
routine preoperative tests.
Because prevaccination samples from tonsils and nasal mucosa
were not available, results from postvaccination samples from ton-
sils and nasal mucosa were compared with data from a recent and
comparable study that included 9 male and 10 female nonvacci-
nated volunteers (mean age, 28 years) [5]. These subjects belonged
to the same patient group, had similar basal anti– influenza virus
antibody levels, and had not recently been vaccinated. Age and
sex distribution were similar in the 2 groups.
HAI assay. The vaccine strains (from the 2000/2001 influenza
season) A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2),
and B/Yamanashi/166/98 were propagated in embryonated hens’
eggs and used as viral antigens in the HAI test. Serum was pretreat-
ed with receptor-destroying enzyme (Denka Seiken) overnight at
37C and then incubated for 1 h at 56C to remove nonspecific in-
hibitors. The HAI test was done with 8 HA units of virus and 0.7%
(vol/vol) turkey erythrocytes, as described elsewhere [2, 6]. A serum
HAI titer of >40 has been deemed to be protective [7].
ELISA. The concentrations of anti– influenza virus antibodies
in serum and oral fluid were measured by ELISA [2–4]. Purified
surface glycoproteins (gift of Medeva Pharma) from the vaccine
strains were used as antigens. Ninety-six–well microtiter plates
were coated with 0.1mg of HA in 100mL of PBS per well overnight
at 4C. The wells were blocked with 10% fetal calf serum (FCS) in
PBS before serum and oral fluid samples were applied in duplicate
dilution series. For detection, we used peroxidase-conjugated goat
anti-human polyvalent immunoglobulins (A-8400; Sigma). The
reaction was developed with 100 mL/well o-phenylenediamine (P-
2045; Dako) at a concentration of 0.7 mg/mL and stopped with
100 mL of 1 M H2SO4 per well. The plates were thoroughly washed
between each step with multiple washes of PBS. The results were
read with a Mikrotek Emax microplate reader and analyzed with
SoftMax Pro software (Apple Macintosh version). A standard
curve was prepared with anti-human polyvalent immunoglobulins
(I-8758; Sigma) as capture antibody (1:100 dilution) and purified
human immunoglobulin (I-4506; Sigma) as the standard. The stan-
dard was prepared as a duplicate dilution series on each microtiter
plate analyzed.
Enzyme-linked immunospot (ELISpot) assay. Lymphocytes
were isolated from the blood, tonsils, and nasal tissue with use of
Lymphoprep (Nycomed Pharma) and were analyzed by the ELI-
Spot method [2, 8]. The ELISpot plates were coated with 1 mg of
HA per well. The ELISpot assay was done aseptically. Wells were
blocked with cell-culture medium (RPMI 1640 medium containing
10% FCS and 2 mM glutamine). Lymphocytes from blood and ton-
sils were added to the plates at concentrations of 5 £ 105 lympho-
cytes/well in multiple wells. The number of lymphocytes isolated
from the nasal tissue did not allow such concentrations; instead,
all isolated cells were divided into duplicate wells for each influen-
za virus strain (5 £ 103 to 1 £ 105 lymphocytes/well). After over-
night incubation in a cell-culture incubator (37C in air with 5%
CO2), the plates were washed, and binding of anti– influenza virus
antibodies was detected by peroxidase-conjugated anti-human
polyvalent immunoglobulins from goat (A-8400; Sigma). The sub-
strate used for detection of the spots was 4-chloro-1-naphthol (C-
6788; Sigma). The plates were allowed to dry, after which the spots
in each well were counted manually in a stereomicroscope (M3C,
type S, Wild) at £16–25 magnification.
Statistical analysis. Comparisons were made with Student’s t
test (paired and unpaired), using GraphPad Prism v3.0 on an Apple
Macintosh computer. Results of a statistical test were considered
to be significant when P, :05 and to be borderline when :05<
P< :07.
Results
In the present study, the effect of parenterally administered in-
fluenza vaccine on systemic and local mucosal immune responses
was investigated in 23 volunteers. Although the subjects had recur-
rent tonsillitis, they were otherwise healthy, with no infection in
the 3–4 months before tonsillectomy was performed. They had
not experienced influenza virus infection or been vaccinated
against influenza during the previous year, and they had no his-
tory of allergy (as ascertained by oral communication with the
patients). This information was also confirmed by routine diag-
nostic analysis (data not shown).
Serum HAI antibody titers. Serum samples were collected
immediately before vaccination and 7 days after vaccination,
when tonsillectomy was done. The serum samples were tested
by the HAI assay (figure 1), a common method for assessing pro-
tective serum antibody responses. An HAI titer of >40 is con-
sidered to give protection against influenza virus infection [7].
None of the 23 volunteers in this study had HAI titers of >40
to the H1N1 virus before vaccination, whereas 30% had protec-
tive titers to the H3N2 strain and 43% to the B strain. After vac-
cination, these proportions increased to 83%, 70%, and 83% for
the H1N1, H3N2, and B strains, respectively. The increase in HAI
titers was statistically significant for all 3 virus strains (H1N1,
P , :0001; H3N2, P , :0001; B, P ¼ :0004).
Influenza virus–specific antibody concentrations in serum
and oral fluid. The levels of influenza virus–specific anti-
bodies in serum were measured by ELISA (figure 2). This assay
tests the same immunologic response as does the HAI assay,
but, because there are some fundamental differences between
these 2 methods, each measures a different subpopulation of influ-
enza virus–specific serum antibodies. Although ELISA is con-
siderably more sensitive, a protective threshold has not yet
been established, as has been done for the HAI assay.
The mean prevaccination serum concentration of antibodies
to the H1N1 strain was 26 mg/mL; to the H3N2 strain, 21 mg/mL;
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and to the B strain, 13mg/mL. After vaccination, the serum anti-
body concentrations increased significantly, to 137 mg/mL (P¼
:0029), 69 mg/mL (P , :0001), and 227 mg/mL (P ¼ :0006),
respectively.
In an earlier study [4], we found that influenza virus–specific
antibodies in oral fluid (saliva) consist mainly of secretory IgA1.
In the present study, we measured the concentration of total in-
fluenza virus–specific antibodies in the oral fluid (figure 3). The
mean levels of prevaccination influenza virus–specific anti-
bodies were 26 ng/mL, 29 ng/mL, and 35 ng/mL, respectively,
to the H1N1, H3N2, and B vaccine strains. Seven days after
vaccination, the concentrations in the oral fluid of antibodies
specific to the H1N1 and B strains rose significantly, to 65 ng/
mL (P , :0001) and 88 ng/mL (P , :0001), respectively. The
response to the H3N2 virus increased 7 days after vaccination
to a mean concentration of 99 ng/mL. This change in mean con-
centration was borderline, not statistically significant (P ¼ :0664),
perhaps because of an outlying value.
Levels of influenza virus–specific ASCs. Lymphocytes
were isolated from peripheral blood, tonsils, and nasal mucosal
biopsy samples. Blood was obtained immediately before and 7
days after vaccination, whereas tonsils and nasal mucosa were
collected at 7 days after vaccination only.
The numbers of influenza virus–specific ASCs against the
vaccine viruses in peripheral blood were very low (mean, ,1
ASC per 106 lymphocytes) before vaccination (figure 4).
These numbers increased significantly by 7 days after vacci-
nation, to mean values of 1419 (P ¼ :0011), 370 (P ¼ :0170),
and 532 (P ¼ :0215) influenza virus–specific ASCs per 106
lymphocytes for the H1N1, H3N2, and B strains, respectively.
In the tonsils, the mean numbers of influenza virus–specific
ASCs were 188 (H1N1), 36 (H3N2), and 25 (B strain) ASCs per
106 lymphocytes at 7 days after vaccination. When these results
were compared with data from a recent study [5] of nonvacci-
nated subjects, we found significantly higher numbers of ASCs
specific to the H1N1 (P¼ :0143) and H3N2 (P¼ :0032) strains
in the vaccinated volunteers. For the B strain, this increase was
borderline (P¼ :0582).
The frequencies of influenza virus–specific ASCs in nasal
mucosal tissue were higher than the frequencies in tonsils but
Figure 1. Mean serum hemagglutination inhibition (HAI) titer against 3 vaccine viruses (H1N1, H3N2, and B strains) for each subject (n ¼ 23)
immediately before (open symbols) and 7 days after (solid symbols) vaccination. The horizontal bar in each column represents the mean value. The
shaded area indicates nonprotective HAI titers (,40). *Significant difference between prevaccination and day-7 samples (P , :05, by paired t
test).
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lower than frequencies in peripheral blood at 7 days after vacci-
nation. The mean numbers of influenza virus–specific ASCs per
106 lymphocytes were 693 (H1N1), 673 (H3N2), and 229 (B
strain). The numbers of influenza virus–specific ASCs in the
nasal mucosa did not differ significantly between vaccinated and
nonvaccinated subjects (H1N1, P ¼ :1937; H3N2, P ¼ :3454;
B strain, P ¼ :5673) [5].
Discussion
Our long-term strategy has been to delineate the systemic and
local immune responses to influenza vaccination. Such knowl-
edge is important for future vaccine development strategies.
The aim of the present study was to examine the levels of influ-
enza virus–specific ASCs locally in tonsils and nasal mucosa
after parenteral vaccination.
The subjects in this study were selected from among young
adult patients scheduled to undergo tonsillectomy who were
otherwise healthy. The use of young adults ensured that all sub-
jects had been previously primed (infected) with influenza virus
and thus had some level of influenza virus–specific memory
cells. This study was carried out during a time of no local influ-
enza activity (autumn 2000, Norway). None of the subjects had
experienced influenza virus infection or vaccination during the
preceding influenza season (1999–2000). This was experimen-
tally supported by the HAI assay results, which showed that
none of the subjects had serum HAI titers of .80 before vacci-
nation. The serum ELISA titers and the HAI titers showed the
same trend in immunologic response. Vaccination induced a
significant increase in serum anti–influenza virus antibody pro-
duction (HAI and ELISA), which is in line with findings pub-
lished elsewhere [2, 3].
In previous studies [2–4], we found that the influenza virus–
specific antibodies in the oral fluid (saliva) consist mainly of se-
cretory IgA1, that the antibody response is first detected as early
as 5–7 days after vaccination, and that the elevated antibody re-
sponse lasts for 3–5 days. We therefore decided in the present
study to sample oral fluid at 7 days after vaccination and to
test only for total anti– influenza virus antibodies. We observed
a significant increase in levels in oral fluid of antibody to the
Figure 2. Total concentration of influenza virus–specific antibodies to 3 vaccine viruses (H1N1, H3N2, and B strains) for each subject (n ¼ 23)
in serum immediately before (open symbols) and 7 days after (solid symbols) vaccination. The horizontal bar in each column indicates the mean
value. *Significant difference between prevaccination and day-7 samples (P , :05, by paired t test).
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H1N1 and B strains after vaccination; these results support ear-
lier findings [3, 4]. The increase in the immune response to the
H3N2 strain was borderline (P ¼ :0664). When the statistical
analysis was repeated after removal of 1 far-outlying value pair,
P dropped to , .0001.
The level of influenza virus–specific ASCs in the blood was
very low before vaccination, with a frequency of1027 lympho-
cytes, compared with levels in tonsils and nasal mucosa. This
level increased strongly, by a magnitude of nearly 4 log10, after
vaccination. The basal level of influenza virus–specific ASCs
in the tonsils was 2–3 log10 higher than the level in peripheral
blood. Vaccination induced a significant increase in influenza
virus–specific tonsillar ASCs against 2 of the viruses (H1N1
and H3N2), whereas the increase of ASCs to the B virus was
borderline (P ¼ :0582). The numbers of influenza virus–specific
ASCs in blood and tonsils were similar to those observed in our
previous studies [2, 3].
In all sample material tested thus far, we found a significant
increase in levels of influenza virus–specific antibodies and
ASCs after vaccination. It was surprising to discover that the
numbers of influenza virus–specific ASCs in the nasal mucosa
did not vary significantly between vaccinated and nonvacci-
nated subjects. The nasal mucosa is an important tissue for pro-
tection against influenza virus infection, and the observed in-
crease in anti– influenza virus antibodies in the oral fluid may
originate from a source other than lamina propria in the nasal
mucosa. A likely origin is a local secondary lymphoid site (e.g.,
the tonsils) or discrete lymphoid tissue (e.g., salivary glands).
The most important aspect of this study is the examination of
ASCs in the nasal mucosa, the main site of influenza virus infec-
tion. Data on the response of the humoral immune system in
the upper respiratory tract mucosa of humans to influenza vacci-
nation and infection are scarce. This is mainly because of the
methodologic difficulties and ethical aspects associated with
obtaining such samples from humans. However, several studies
in animals have emerged recently that describe the immune re-
sponses in the nasal mucosa and nasal-associated lymphoid
tissue. As is true for humans [2, 3, 9], parenteral influenza vac-
cination produces mainly a systemic response in animals, with
a poor local immune response [10, 11]. When mice were immu-
Figure 3. Total concentration of influenza virus–specific antibodies to 3 vaccine viruses (H1N1, H3N2, and B strains) for each subject
(n ¼ 23) in oral fluid immediately before (open symbols) and 7 days after (solid symbols) vaccination. The horizontal bar in each column indi-
cates the mean value. *Significant difference between prevaccination and day-7 samples (P , :05, by paired t test).
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nized by the oral or nasal route, either with live attenuated vac-
cine or with killed split virus combined with an adjuvant, the
local immune response induced specific T and B cell responses
with an enrichment of these cell types in the local mucosa [12–
15]. The kinetics of these immune responses [11, 13] was simi-
lar to that seen in our previously published studies in humans
[2–4]. In addition, parenteral influenza vaccination appears to
favor a Th2 response, whereas infection promotes a Th1 re-
sponse [14, 15].
An important observation in our study is that the frequency of
influenza virus–specific ASCs in the nasal mucosa was 10–100
times higher than the frequency found in peripheral blood and
tonsils without any recent influenza virus stimulation and at a
time during which no influenza activity was seen in the local
community [5]. We have suggested that the basal level of influ-
enza virus–specific ASCs in the upper respiratory tract mucosa
may be important (crucial) in maintaining protection against in-
fluenza. A decrease in this level below a certain threshold may
take several years after an infection to occur and renders the
subject susceptible to infection. Nasal immunization can induce
a long-lasting response lasting for.8 months in mice [16]. Whether
this long-lasting response is due to the presence of long-lived
(.1 year) plasma cells or to continuous unspecific restimulation
and activation of the plasma/memory cells is still to be determined
[11, 16, 17].
The absence of immune response in the nasal mucosa may in-
dicate a lack of appropriate local influenza virus stimulation. An
apparent drawback to traditional parenteral (intramuscular or
subcutaneous) vaccines is that they induce a weak and short-
lived local mucosal immune response. Another concern associ-
ated with the current vaccine strategy is that repeated annual
vaccination may drive the type of immune response from a local
to a systemic response. This may also explain why, in some
studies, the effectiveness of the influenza vaccine is poor. It is
therefore our opinion that future influenza vaccine development
should include vaccines that more closely imitate natural infec-
tion and/or stimulate the local mucosa in the upper respiratory
tract.
Figure 4. No. of influenza virus–specific antibody-secreting cells (ASCs) to 3 vaccine viruses (H1N1, H3N2, and B) for each subject in periph-
eral blood, tonsils, and nasal mucosa immediately before vaccination (or in nonvaccinated subjects) (open symbols; day 0) and 7 days after (solid
symbols) influenza virus vaccination. (Because we lacked prevaccination samples from tonsils and nasal mucosa, comparable data from nonvacci-
nated subjects were obtained from a recent study [5].) The horizontal line in each column indicates the mean value. *Significant difference between
this sample and the paired basal level sample (P , :05, by paired t test for blood and by unpaired t test for tonsils and nasal mucosa).
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High prevalence of influenza specific antibody secreting cells in nasal
mucosa. Scand J Immunol 2001;54:243–7.
6. Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for labora-
tory-based influenza surveillance. Washington, DC: US Department of
Health and Human Services, 1982.
7. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum
haemagglutination-inhibiting antibody in protection against challenge
infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:
767–77.
8. Czerkinsky C, Svennerholm AM, Quiding M, Jonsson R, Holmgren J.
Antibody-producing cells in peripheral blood and salivary glands after
oral cholera vaccination of humans. Infect Immun 1991;59:996–1001.
9. Muszkat M, Yehuda AB, Schein MH, et al. Local and systemic immune response
in community-dwelling elderly after intranasal or intramuscular immuni-
zation with inactivated influenza vaccine. J Med Virol 2000;61:100–6.
10. Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human
immune responses to influenza virus vaccines administered by systemic
or mucosal routes. Vaccine 1995;13:1013–22.
11. Larsen DL, Karasin A, Zuckermann F, Olsen CW. Systemic and mucosal
immune responses to H1N1 influenza virus infection in pigs. Vet Micro-
biol 2000;74:117–31.
12. Wu HY, Nguyen HH, Russell MW. Nasal lymphoid tissue (NALT) as a
mucosal immune inductive site. Scand J Immunol 1997;46:506–13.
13. Tamura S, Iwasaki T, Thompson AH, et al. Antibody-forming cells in the
nasal-associated lymphoid tissue during primary influenza virus infec-
tion. J Gen Virol 1998;79:291–9.
14. Hiroi T, Iwatani K, Iijima H, Kodama S, Yanagita M, Kiyono H. Nasal
immune system: distinctive Th0 and Th1/Th2 type environments in
murine nasal-associated lymphoid tissues and nasal passage, respec-
tively. Eur J Immunol 1998;28:3346–53.
15. Matsuo K, Iwasaki T, Asanuma H, et al. Cytokine mRNAs in the nasal-
associated lymphoid tissue during influenza virus infection and nasal
vaccination. Vaccine 2000;18:1344–50.
16. Wu HY, Nikolova EB, Beagley KW, Russell MW. Induction of antibody-
secreting cells and T-helper and memory cells in murine nasal lymphoid
tissue. Immunology 1996;88:493–500.
17. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to
long-lived plasma cells. Immunity 1998;8:363–72.
Brokstad et al.884 JID 2002;185 (1 April)
